https://bioscibd.pages.dev/author/medwards/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/category/trends/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/author/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/category/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/les-2021/2021-09-01T16:00:00-08:00monthly0.5https://bioscibd.pages.dev/compulsory-license-provisions/2020-11-01T08:30:00-08:00monthly0.5https://bioscibd.pages.dev/category/deal-terms/2020-11-01T08:30:00-08:00monthly0.5https://bioscibd.pages.dev/category/biofi/2020-09-01T09:00:00-08:00monthly0.5https://bioscibd.pages.dev/indomitable-ipo-window/2020-09-01T09:00:00-08:00monthly0.5https://bioscibd.pages.dev/recent-oncology-trends/2020-06-29T18:45:56+00:00monthly0.5https://bioscibd.pages.dev/whos-on-first/2020-04-24T19:16:50+00:00monthly0.5https://bioscibd.pages.dev/antiviral-alliances-covid19/2020-04-05T18:32:10+00:00monthly0.5https://bioscibd.pages.dev/contingent-value-rights/2020-03-08T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/negotiating-what-if/2019-11-09T11:27:29-08:00monthly0.5https://bioscibd.pages.dev/biopharma-upfront-payments/2019-05-30T17:15:37-08:00monthly0.5https://bioscibd.pages.dev/recent-efr-trends/2019-02-05T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/biopharma-milestone-payments/2019-01-06T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/io-alliances/2018-10-13T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/how-far-you-can-go/2018-06-08T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/sharing-the-wealth/2018-02-18T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/best-biotech-window/2018-01-01T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/changing-the-deal/2017-10-12T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/dawn-of-post-venture-era/2017-06-25T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/effective-royalty-rates/2017-03-25T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/yours-mine-ours/2016-10-30T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/top-pharma-vs-major-biotech/2016-06-04T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/orphan-drug-alliances/2016-03-23T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/biopharma-copromotion-success/2016-02-25T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/university-licenses/2016-02-15T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/biopharma-in-2015/2015-10-25T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/royalty-obligations/2015-10-23T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/platform-technologies/2015-05-13T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/2014-year-review/2015-01-05T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/bridging-the-valuation-gap/2014-11-21T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/demand-dividend/2013-02-11T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/biotech-ipos-springboard-for-success/2013-01-24T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/biotech-sell-side-research-a-retrospective-analysis/2013-01-24T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/category/sell-side/2013-01-24T10:28:37-08:00monthly0.5https://bioscibd.pages.dev/contact/monthly0.5https://bioscibd.pages.dev/pages/monthly0.5